Q-Line Biotech's Days Sales Outstanding for the
six
months ended in Mar. 2025 was 63.42.
Q-Line Biotech's Days Inventory for the
six
months ended in Mar. 2025 was 196.58.
Q-Line Biotech's Days Payable for the
six
months ended in Mar. 2025 was 115.52.
Therefore, Q-Line Biotech's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2025 was 144.48.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Q-Line Biotech Cash Conversion Cycle Related Terms
Q-Line Biotech Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Cash Conversion Cycle Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Cash Conversion Cycle
79.62
128.93
144.48
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Cash Conversion Cycle
79.62
128.93
144.48
NSE:QLINE vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Q-Line Biotech's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Q-Line Biotech's Cash Conversion Cycle for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech (NSE:QLINE) has a Cash Conversion Cycle of 144.48 as of Mar. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Q-Line Biotech and its competitors.
Is Q-Line Biotech's Cash Conversion Cycle too high?
Q-Line Biotech's current Cash Conversion Cycle is 144.48. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.39. Q-Line Biotech's value of 144.48 is 7.6% below this industry median. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Cash Conversion Cycle compare to ABT and SYK?
Q-Line Biotech's Cash Conversion Cycle of 144.48 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.39. Q-Line Biotech's value of 144.48 is 7.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.39, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current Cash Conversion Cycle of 144.48 is 7.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current Cash Conversion Cycle is 144.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Cash Conversion Cycle of 144.48. The current Cash Conversion Cycle is 144.48 and 7.6% below the Medical Devices & Instruments industry median of 156.39. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Cash Conversion Cycle is 144.48 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 